Up next

Autoplay

Pharmacology of Secukinumab (Cosentyx) ; Mechanism of action, Uses, Effects, Pharmacokinetics

1 Views • 08/18/25
Share
Side Effects
Side Effects
Subscribers
0

Secukinumab (Cosentyx) is a human monoclonal antibody that targets interleukin-17A (IL-17A), a cytokine involved in autoimmune and inflammatory diseases. It is used for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.

Pharmacology
Mechanism of Action: Secukinumab binds to IL-17A, preventing its interaction with IL-17 receptors. This reduces inflammation by inhibiting the release of proinflammatory cytokines.

Absorption: Administered subcutaneously, with peak levels reached in 2 to 6 days.

Metabolism: Cleared via proteolytic degradation.

Elimination: Slow clearance, with a half-life of ~22 days.

Clinical Uses
Plaque Psoriasis: Used for moderate-to-severe cases in adults.

Psoriatic Arthritis: Can be used alone or with non-biologic DMARDs.

Ankylosing Spondylitis: Helps reduce spinal inflammation and stiffness.

Hidradenitis Suppurativa: Approved for moderate-to-severe cases.

Adverse Effects
Infections (upper respiratory tract infections, fungal infections).

Hypersensitivity reactions (including anaphylaxis).

Exacerbation of Crohn’s disease (use with caution in patients with inflammatory bowel disease).

Avoid live vaccines during treatment.

#Secukinumab

Show more
0 Comments sort Sort By

Up next

Autoplay